Is radiofrequency ablation treatment a clinically and cost effective treatment to be offered to people with renal cancer in NHSScotland?
Kelly J, Wilson L
Record ID 32013000463
English
Authors' recommendations:
There is no evidence from randomised trials on the effectiveness of radiofrequency ablation (RFA) compared to surgical resection for renal cell carcinoma (RCC).
Evidence from a meta-analysis of case series comparing RFA with other forms of ablation suggest that it may be a viable approach for small renal masses based on short-term oncological outcomes.
There is insufficient evidence to determine whether or not RFA would be considered cost effective for RCC at currently accepted thresholds in NHSScotland. One cost utility analysis from the United States of America was identified but its generalisability to NHSScotland is questionable.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg_-_evidence_notes/evidence_note_40.aspx
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Scotland, United Kingdom
MeSH Terms
- Kidney Neoplasms
- Cost-Benefit Analysis
- Scotland
Contact
Organisation Name:
Scottish Health Technologies Group
Contact Address:
Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998
Contact Name:
his.shtg@nhs.scot
Contact Email:
his.shtg@nhs.scot
Copyright:
Healthcare Improvement Scotland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.